Related Experiment Videos
Clinical experience with intravenous Augmentin in the treatment of paediatric infections
Insights
Intravenous Augmentin (amoxicillin/clavulanic acid) demonstrated high clinical and bacteriological success in children with lower respiratory tract infections. This antibiotic formulation proved effective and well-tolerated in the studied pediatric population.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
- Antimicrobial Therapy
Background:
- Lower respiratory tract infections (LRTI) are common in children.
- Effective antibiotic treatment is crucial for managing pediatric LRTI.
- Intravenous Augmentin, a combination of amoxicillin and clavulanic acid, is a potential therapeutic option.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of intravenous Augmentin in children.
- To assess bacteriological success rates in pediatric patients treated with intravenous Augmentin.
- To determine the tolerability of intravenous Augmentin in a pediatric cohort.
Main Methods:
- An open-label study was conducted involving 58 children (mean age 6 years).
- Patients received intravenous Augmentin at a dosage of 100-200 mg/kg/day in 3-4 divided doses.
- The primary indication for treatment was lower respiratory tract infections.
Main Results:
- Complete clinical cure or significant improvement was observed in all assessable patients.
- Bacteriological success was achieved in 92% of assessable cases.
- Mild, transient exanthema occurred in two patients after switching to oral Augmentin, requiring no further intervention.
Conclusions:
- Intravenous Augmentin is highly effective for treating lower respiratory tract infections in children.
- The antibiotic demonstrated a favorable safety profile with minimal adverse events.
- Augmentin is a viable treatment option for pediatric patients requiring parenteral antimicrobial therapy.
Abstract:
The clinical efficacy of intravenous Augmentin (a formulation containing amoxycillin plus clavulanic acid) was investigated in an open study in fifty-eight children with a mean age of 6 years (range 1-15 years). The normal dosage was in the range 100-200 mg/kg/day Augmentin, administered parenterally by short i.v. infusion in 3 or 4 divided doses. Most patients were hospitalised for lower respiratory tract infections. Complete clinical cure or distinct clinical improvement was achieved in all assessable cases. Bacteriological success was obtained in 92% of the assessable cases. In two patients, mild, transient exanthema was noted after i.v. Augmentin was replaced by oral Augmentin. No additional therapeutic measures were required.